• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 15-12G filed by Cardiovascular Systems Inc.

    5/8/23 6:00:37 AM ET
    $CSII
    Medical/Dental Instruments
    Health Care
    Get the next $CSII alert in real time by email
    15-12G 1 tm2314457d1_1512g.htm 15-12G

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

     

    FORM 15

     

     

     

    CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.

     

    Commission File Number: 000-52082

     

     

     

    CARDIOVASCULAR SYSTEMS, INC.

    (Exact name of registrant as specified in its charter)

     

     

     

    1225 Old Highway 8 Northwest
    St. Paul, Minnesota 55112-6416
    Tel: (651) 259-1600

    (Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)

     

    Common Stock, $0.001 par value per share

    (Title of each class of securities covered by this Form)

     

    None

    (Titles of all other classes of securities for which a duty to file reports under section 13(a) or 15(d) remains)

     

     

     

    Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:

     

    Rule 12g-4(a)(1) x
    Rule 12g-4(a)(2) ¨
    Rule 12h-3(b)(1)(i) x
    Rule 12h-3(b)(1)(ii) ¨
    Rule 15d-6 ¨
    Rule 15d-22(b) ¨

     

    Approximate number of holders of record as of the certification or notice date: 1

     

     

     

     

     

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, Cardiovascular Systems, Inc. has caused this certification/notice to be signed on its behalf by the undersigned duly authorized person.

     

    Date:    May 8, 2023 CARDIOVASCULAR SYSTEMS, INC.
       
      By: /s/ John A. McCoy, Jr.
        John A. McCoy, Jr.
        President and Treasurer

     

     

     

    Get the next $CSII alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CSII

    DatePrice TargetRatingAnalyst
    12/21/2022$15.00Equal Weight
    Barclays
    12/14/2022$25.00Buy
    Lake Street
    3/2/2022$22.00Underperform
    BofA Securities
    2/4/2022$25.00 → $20.00Outperform
    SVB Leerink
    11/17/2021Buy → Hold
    Needham
    11/10/2021Buy → Neutral
    Guggenheim
    11/10/2021$45.00 → $40.00Outperform
    SVB Leerink
    9/23/2021$50.00 → $49.00Buy
    Needham
    More analyst ratings

    $CSII
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Barclays initiated coverage on Cardiovascular Systems with a new price target

    Barclays initiated coverage of Cardiovascular Systems with a rating of Equal Weight and set a new price target of $15.00

    12/21/22 7:41:39 AM ET
    $CSII
    Medical/Dental Instruments
    Health Care

    Lake Street initiated coverage on Cardiovascular Systems with a new price target

    Lake Street initiated coverage of Cardiovascular Systems with a rating of Buy and set a new price target of $25.00

    12/14/22 9:03:31 AM ET
    $CSII
    Medical/Dental Instruments
    Health Care

    BofA Securities resumed coverage on Cardiovascular Systems with a new price target

    BofA Securities resumed coverage of Cardiovascular Systems with a rating of Underperform and set a new price target of $22.00

    3/2/22 7:23:56 AM ET
    $CSII
    Medical/Dental Instruments
    Health Care

    $CSII
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    $CSII
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    $CSII
    SEC Filings

    View All

    Cytek Biosciences Set to Join S&P SmallCap 600

    NEW YORK, April 25, 2023 /PRNewswire/ -- Cytek Biosciences Inc (NASD:CTKB) will replace Cardiovascular Systems Inc. (NASD:CSII) in the S&P SmallCap 600 effective prior to the opening of trading on Monday, May 1. S&P 500 and 100 constituent Abbott Laboratories (NYSE:ABT) is acquiring Cardiovascular Systems in a deal expected to be completed soon, pending final closing conditions. Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index Name       Action Company Name Ticker GICS Sector May 1, 2023 S&P SmallCap 600 Addition Cytek Biosciences CTKB Health Care S&P SmallCap 600 Deletion Cardiovascular Systems CSII Health C

    4/25/23 5:54:00 PM ET
    $ABT
    $CSII
    $CTKB
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Dental Instruments
    Biotechnology: Laboratory Analytical Instruments

    Cardiovascular Systems, Inc. Completes Enrollment of ECLIPSE Clinical Trial

    Largest randomized coronary atherectomy trial ever conducted Cardiovascular Systems, Inc. (CSI) (NASDAQ:CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, announced today the company completed the enrollment of its 2,000 patient ECLIPSE coronary trial. ECLIPSE is a prospective, multi-center, randomized clinical trial of approximately 2,000 subjects with severely calcified coronary lesions in the United States. Half of the participants received orbital atherectomy prior to drug-eluting stent implantation, while the other half received conventional angioplasty, including speci

    4/3/23 4:05:00 PM ET
    $CSII
    Medical/Dental Instruments
    Health Care

    Cardiovascular Systems, Inc. Reports Fiscal 2023 Second Quarter Financial Results

    Cardiovascular Systems, Inc. (CSI®) (NASDAQ:CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, today reported financial results for its second quarter, ended December 31, 2022. Second Quarter Financial Highlights CSI's fiscal 2023 second quarter revenues were $61.5 million, representing an increase of $2.3 million, or 3.9% compared to the second quarter last year. Gross profit margin was 70.0%. Selling, general and administrative expenses were $41.6 million, an increase of $1.2 million, or 3.1%. Research and development expenses increased 7.4% to $9.5 million due to the timin

    2/8/23 6:12:00 PM ET
    $ABT
    $CSII
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Dental Instruments

    SEC Form 4 filed by Womack Kelvin K.

    4 - Cardiovascular Systems Inc (0001180145) (Issuer)

    4/27/23 4:35:24 PM ET
    $CSII
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Paulsen Erik

    4 - Cardiovascular Systems Inc (0001180145) (Issuer)

    4/27/23 4:38:00 PM ET
    $CSII
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Points Jeffrey S.

    4 - Cardiovascular Systems Inc (0001180145) (Issuer)

    4/27/23 4:37:02 PM ET
    $CSII
    Medical/Dental Instruments
    Health Care

    SEC Form 15-12G filed by Cardiovascular Systems Inc.

    15-12G - Cardiovascular Systems Inc (0001180145) (Filer)

    5/8/23 6:00:37 AM ET
    $CSII
    Medical/Dental Instruments
    Health Care

    SEC Form S-8 POS filed by Cardiovascular Systems Inc.

    S-8 POS - Cardiovascular Systems Inc (0001180145) (Filer)

    5/1/23 6:03:42 AM ET
    $CSII
    Medical/Dental Instruments
    Health Care

    SEC Form S-8 POS filed by Cardiovascular Systems Inc.

    S-8 POS - Cardiovascular Systems Inc (0001180145) (Filer)

    5/1/23 6:05:14 AM ET
    $CSII
    Medical/Dental Instruments
    Health Care

    $CSII
    Financials

    Live finance-specific insights

    View All

    Cardiovascular Systems, Inc. Reports Fiscal 2023 Second Quarter Financial Results

    Cardiovascular Systems, Inc. (CSI®) (NASDAQ:CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, today reported financial results for its second quarter, ended December 31, 2022. Second Quarter Financial Highlights CSI's fiscal 2023 second quarter revenues were $61.5 million, representing an increase of $2.3 million, or 3.9% compared to the second quarter last year. Gross profit margin was 70.0%. Selling, general and administrative expenses were $41.6 million, an increase of $1.2 million, or 3.1%. Research and development expenses increased 7.4% to $9.5 million due to the timin

    2/8/23 6:12:00 PM ET
    $ABT
    $CSII
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Dental Instruments

    Cardiovascular Systems, Inc. to Host Earnings Conference Call on February 9, 2023

    Cardiovascular Systems, Inc. (NASDAQ:CSII) plans to announce its operating results for the quarter ended December 31, 2022 before the market opens on Thursday, February 9, 2023, and will host a conference call at 9:00 a.m. ET that day to discuss those results. Click here to access the live webcast. A replay will be available later the same day. Click here to register for the conference call. About Cardiovascular Systems, Inc. Cardiovascular Systems, Inc., based in St. Paul, Minn., is a medical device company focused on developing and commercializing innovative solutions for treating vascular and coronary disease. The company's orbital atherectomy system treats calcified and fibrotic pla

    1/19/23 7:00:00 AM ET
    $CSII
    Medical/Dental Instruments
    Health Care

    Cardiovascular Systems, Inc. Reports Fiscal 2023 First Quarter Financial Results

    Conference Call Scheduled for Today, November 3, 2022, at 8:00 a.m. CT (9:00 a.m. ET)  Revenues of $59.7 million increased 2.2% compared to first quarter last year Management reiterates fiscal 23 revenue guidance of $255 million to $265 million, representing 8% to 12% growth Cardiovascular Systems, Inc. (CSI®) (NASDAQ:CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, today reported financial results for its first quarter, ended September 30, 2022. Executive Commentary – Scott Ward, Chairman, President and CEO "We are pleased with the state of our business and our perfor

    11/3/22 7:00:00 AM ET
    $CSII
    Medical/Dental Instruments
    Health Care

    $CSII
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Cardiovascular Systems Inc. (Amendment)

    SC 13G/A - Cardiovascular Systems Inc (0001180145) (Subject)

    2/13/24 3:24:48 PM ET
    $CSII
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by Cardiovascular Systems Inc. (Amendment)

    SC 13G/A - Cardiovascular Systems Inc (0001180145) (Subject)

    2/14/23 9:00:06 AM ET
    $CSII
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by Cardiovascular Systems Inc. (Amendment)

    SC 13G/A - Cardiovascular Systems Inc (0001180145) (Subject)

    2/13/23 1:26:27 PM ET
    $CSII
    Medical/Dental Instruments
    Health Care

    $CSII
    Leadership Updates

    Live Leadership Updates

    View All

    Big Sky Biomedical Appoints Ryan Egeland, M.D., Ph.D., M.B.A., as Managing Director

    MINNEAPOLIS, March 7, 2022 /PRNewswire-PRWeb/ -- Big Sky Biomedical, a leading-edge medical device and health technology incubator, announced today that it has appointed Ryan Egeland, M.D., Ph.D., M.B.A., as Managing Director. "Big Sky Biomedical was founded to enhance early-stage innovation and development in some of the fastest growing segments of healthcare, including neurovascular, structural heart, and regenerative medicine," said Dr. Egeland. "I'm extremely excited to apply my scientific, medical, and commercial experience to our portfolio companies in a much broader and deeper capacity. Alongside our exceptional teams of engineers, scientists, operators, and physician partners, I loo

    3/7/22 12:00:00 PM ET
    $CSII
    $MDT
    Medical/Dental Instruments
    Health Care
    Biotechnology: Electromedical & Electrotherapeutic Apparatus

    Cardiovascular Systems, Inc. Appoints Jeffery W. Chambers, M.D., as Chief Medical Officer

    Cardiovascular Systems, Inc. (CSI) (NASDAQ:CSII), a medical device company developing and commercializing innovative interventional treatment systems for peripheral and coronary vascular disease, today announced that it has appointed Jeffery W. Chambers, M.D., as Chief Medical Officer. "CSI is developing an exciting product pipeline that targets some of the fastest growing segments of interventional cardiology," said Scott Ward, Chairman, President and Chief Executive Officer. "Jeff brings contemporary interventional cardiology practice and extensive clinical research experience to CSI as we seek to expand our product offering beyond orbital atherectomy. We believe Jeff brings valuable per

    3/4/22 7:00:00 AM ET
    $CSII
    Medical/Dental Instruments
    Health Care

    Beta Bionics Announces the Appointment of Martha Goldberg Aronson as Chair of Its Board of Directors

    CONCORD, Mass.--(BUSINESS WIRE)--Beta Bionics, Inc., a medical technology company focused on the design, development, and commercialization of the iLet® bionic pancreas system, today announced the appointment of Martha Goldberg Aronson as Chair of its Board of Directors, effective immediately. Ms. Aronson, who joined the Beta Bionics Board as a Director in February of 2020, succeeds Ed Damiano, President and Chief Executive Officer of Beta Bionics, who has served as Chair since inception of the company in 2015. Dr. Damiano will remain a member of the Board while continuing to serve in his roles as President and Chief Executive Officer of Beta Bionics. “On behalf of the Board, I am

    2/9/21 4:01:00 PM ET
    $CSII
    $MEI
    $CNMD
    Medical/Dental Instruments
    Health Care
    Electrical Products
    Technology